SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with CetuximabBASEL, Switzerland, January 19, 2023 / B3C newswire / -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combi...

Related Keywords

Leuven ,Region Flamande ,Belgium ,Switzerland ,Richard Sachse ,Karen Geboes ,Eric Van Cutsem ,University Hospital In Leuven Belgium ,Gent University Hospital Belgium ,Department Of Gastrointestinal ,First Patient ,Nanrilkefusp Alfa ,Gent University Hospital ,Professor Karen Geboes ,Digestive Oncology ,University Hospital ,